Stifel Maintains Buy on DexCom, Lowers Price Target to $145
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman maintains a 'Buy' rating on DexCom (NASDAQ:DXCM) but lowers the price target from $155 to $145.
October 10, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the lowered price target from $155 to $145, Stifel maintains a 'Buy' rating on DexCom, indicating continued confidence in the company's performance.
The lowered price target might initially cause some investor concern, potentially leading to short-term price volatility. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could balance out any negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100